Speakers - Sachs Associates

More documents

Recommendations

Info

CONTACT Hans Schambye, MD PhD Chief Executive Officer ADDRESS Ole Maaloes Vej 3 DK-2200 Copenhagen Denmark TELEPHONE +45 26 37 37 26 EMAIL hs@galecto.com YEAR FOUNDED 2011 Galecto Biotech www.galecto.com COMPANY PROFILE Galecto Biotech is a newly founded company, focused on developing novel drugs for the treatment of fibrosis, inflammation and other serious human diseases. The company’s products target galectins, a group of proteins that play important roles in many disorders. Galecto Biotech’s high potency galectin inhibitors may open new treatment possibilities for many patients. The company is led by top-level scientists and biotech executives. Galecto Biotech is located in Medicon Valley in close proximity to the founders’ research groups. MANAGEMENT Hans Schambye, MD PhD, CEO Prof Tariq Sethi, B.Sc., M.A., Ph.D., FRCP, CSO Prof Ulf Nilsson, PhD, Head, Med Chem Prof Hakon Leffler, MD PhD, Head, Immunology & Biology t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
CONTACT Benedikt Timmerman Chief Executive Officer ADDRESS GENTICEL 516 Rue Pierre et Marie Curie 31670 Labege FRANCE TELEPHONE +33 (0)5 61 28 70 60 FAX +33 (0)5 61 28 70 69 EMAIL btimmerm@genticel.com YEAR FOUNDED 2001 Genticel www.genticel.com FINANCIAL SUMMARY Raised EUR 27.5 Mio, of which EUR 8 Mio in subsidies and revenues), in private, VC-backed Seed-, A- and B-rounds. Key investors: • Edmond de Rothschild Investment Partners • IdInvest (Kurma Biofund) • CDC Entreprises (Innobio) • AMUNDI Private Equity COMPANY PROFILE Genticel is a biotechnology company focused on developing multivalent vaccines against Human Papillomavirus (HPV) infections, which are the known cause for several cancers including cervix carcinoma. Genticel’s proprietary vector technology platform, the recombinant Adenylate Cyclase protein vector (CyaA), has the potential to be used for a broad range of vaccine applications as it allows the insertion of large antigens by recombinant DNA technology. This vector is the only system that naturally targets specific antigens directly to and into the cytosol of antigen-presenting cells, leading to a potent and long lasting cellular immune response. ProCervix, Genticel’s lead investigational product has been successfully tested in combination with an established adjuvant in a clinical phase I study. It is a proprietary, first in class HPV16/18 vaccine for the treatment of already infected women with normal cytology or low-grade precancerous lesions, i.e. women who have not yet developed high-grade cervical lesions or cancer. ProCervix is designed to eliminate HPV16 and/ or 18 infected cells and to provide protection against re-infection. The Phase Ib trial (n=47) displayed no dose limiting toxicity and no patient drop-out. The two intradermal injections 6 weeks apart have generally been well tolerated with transient vaccine-related reactions. No treatment-related Serious Adverse Effects were reported. ProCervix induced a dose-dependent immune response as well as viral clearance in a substantial proportion of patients as compared to placebo. IND filing for phase II is scheduled for H1/2013. Heptarvix, complementing Genticel´s HPV pipeline, is a preclinical stage, multivalent HPV vaccine candidate which is designed to provide protection against up to seven oncogenic HPV types. It is based on an adapted proprietary CyaA vector (Vaxiclase). Genticel intends raising additional capital to conduct a PoC Phase 2 trial with ProCervix and advance Heptarvix up to end of preclinical development. MANAGEMENT The management team has jointly 60 years of experience in Pharma & Life Science Industry: Dr Benedikt Timmerman, MBA, PhD, Founder and CEO Dr Marie-Christine Bissery, PhD, PharmD, CSO Mr Martin Koch, MBA, Ing., CFO t back :: next u WELCOME PHARMA LICENSING GROUPS SPEAKERS PRESENTING COMPANIES SUPPORTING ORGANISATIONS ORGANISERS
Page 1 and 2:
B I O T E C H I N E U R O P E I N V
Page 3 and 4:
Events Diary For regular updates, s
Page 5 and 6: Speakers Alexey Eliseev, Managing D
Page 7 and 8: Speakers Blake M. Paterson, Co-Foun
Page 9 and 10: Speakers David Slack, Head of Corpo
Page 11 and 12: Speakers Frank Grams, VP, Head Alli
Page 13 and 14: Speakers Iain Buchanan, CEO, NOXXON
Page 15 and 16: Speakers Juhani Lahdenperä, CEO, H
Page 17 and 18: Speakers Marcel Zwaal, CBO, DCPrime
Page 19 and 20: Speakers Paul Higham, Managing Dire
Page 21 and 22: Speakers Richard Goodfellow, CEO, S
Page 23 and 24: Speakers Søren Moller, Managing In
Page 25 and 26: CONTACT Robert F Burns, PhD Chief E
Page 27 and 28: CONTACTS Rostislav Raykov Chief Exe
Page 29 and 30: CONTACTS Vincent Charlon PhD, CEO Z
Page 31 and 32: CONTACTS Dr Bassam Damaj Chairman,
Page 33 and 34: CONTACT Carina Schmidt Chief Execut
Page 35 and 36: CONTACT Mr Richard Godfrey Chief Ex
Page 37 and 38: CONTACTS Tom Kronbach, PhD Chief Ex
Page 39 and 40: CONTACTS Andreas Caduff, PhD Chief
Page 41 and 42: CONTACTS Dr Blake Paterson Co-Found
Page 43 and 44: CONTACT Wolfgang Kintzel Chief Exec
Page 45 and 46: CONTACT Mike Romanos PhD Chief Exec
Page 47 and 48: CONTACT Harry Welten, MBA Chief Fin
Page 49 and 50: CONTACT Barbara Stiefel Office Mana
Page 51 and 52: CONTACTS Ana Martinez Assistant Jua
Page 53 and 54: CONTACTS Dr Rudi D Neirinckx Chief
Page 55: CONTACT Martin Bonde, PhD, BComm Ch
Page 59 and 60: CONTACT Malcolm Weir Chief Executiv
Page 61 and 62: CONTACTS Mr Paul Higham Chief Execu
Page 63 and 64: CONTACTS Kevin FitzGerald Chief Ope
Page 65 and 66: CONTACT Roel Q. J Schaapveld, PhD,
Page 67 and 68: CONTACT Maaike Vogelezang Managemen
Page 69 and 70: CONTACT Tom Johnston Chief Executiv
Page 71 and 72: CONTACTS Aaron Powers President Dav
Page 73 and 74: CONTACTS General and Media Contact
Page 75 and 76: CONTACTS Martin Welschof Chief Exec
Page 77 and 78: CONTACTS Carlos Buesa Chief Executi
Page 79 and 80: CONTACTS Nick McCooke Chief Executi
Page 81 and 82: CONTACT Dr Erik Buntinx Chief Execu
Page 83 and 84: CONTACT Michael Altorfer, Ph.D. Hea
Page 85 and 86: CONTACT Matthew B. Lehman Chief Ope
Page 87 and 88: ADDRESS Otto-Hahn-Strasse 15 D- 442
Page 89 and 90: CONTACT Dr Roman Schenk Chief Execu
Page 91 and 92: CONTACTS Dr Hans Fliri Chairman Sim
Page 93 and 94: CONTACTS Dr Raúl Insa Chief Execut
Page 95 and 96: CONTACT Dr Johanna Holldack, MD Chi
Page 97 and 98: CONTACT Eduardo Bravo (speaker) Man
Page 99 and 100: CONTACTS Piers Morgan Chief Financi
Page 101 and 102: CONTACT Jakob Knudsen Chief Executi
Page 103 and 104: CONTACTS Dr Sonja Reingruber Chief
Page 105 and 106: Supporting Organisations Citigate D
Page 107 and 108:
Supporting Organisations Life Scien
Page 109 and 110:
Supporting Organisations Swiss Biot
Page 111 and 112:
Supporting Organisations Torreya Pa
Page 113:
B I O T E C H I N E U R O P E I N V
show all

Speakers - Sachs Associates

Create successful ePaper yourself

Delete template?

Save as template?